How much does Ponatinib cost?

Ponatinib (Ponatinib) is indicated for the treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). The drug was discovered, developed and marketed by Ariad Pharmaceuticals. Ariad received approval from the U.S. Food and Drug Administration (FDA) for ponatinib in December 2012 for the treatment of two rare diseases, such as CML and Ph+ ALL. Ariad has received a positive opinion from the European Medicines Agency (EMA) CHMP for the approval of ponatinib in Europe.

Ponatinib is a multi-TKI targetingSRC, ABL, FGFR, PDGFR and VEGFR. It is approved by the FDA as a second-line treatment option for Ph+ CML and Ph+ ALL patients, and is the only approved inhibitor that successfully targets the ABL-T135I mutation. Notably, in preclinical studies, ponatinib has also shown potent anti-tumor properties in other cancers, including lung cancer and glioblastoma (GBM), and Phase II trials in patients with these tumors are ongoing.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.